DOGLIOTTI, Luigi

DOGLIOTTI, Luigi  

Dip. SCIENZE CLINICHE E BIOLOGICHE (attivo dal 01/01/1900 al 30/04/2013)  

Mostra records
Risultati 1 - 20 di 20 (tempo di esecuzione: 0.029 secondi).
Titolo Data di pubblicazione Autore(i) File
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 2012 Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A
Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception 2008 Saini A; Ostacoli L; Negro M; Sguazzotti E; Tosco A; Cracco C; Scarpa RM; Furlan P; Dogliotti L; Berruti A
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome 2008 A. Berruti; F. Vana; M. Tucci; A. Mosca; L. Russo; G. Gorzegno; A. Saini; P. Perotti; M. Tampellini; L. Dogliotti
Chromogranine A serum levels in patients affected by prostate cancer and benign prostate hypertrophy: comparison between two different commercial kits 2005 Bosio A; Berruti A; Zitella A; Mengozzi G; Destefanis P; Bisconti A; Casetta G; Aimo P; Rolle L; Greco A; Dogliotti L; Fontana D; Tizzani A
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. 2006 A Dovio; D Generali; A Berruti; M Tampellini; S Tedoldi; S Bonardi; M Tucci; G Allevi; S Aguggini; M Milani; A Bottini; L Dogliotti; A Angeli
Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects 2005 D. G. Generali; S. Tedoldi; M. Tampellini; A. Berruti; M. Torta; S. Bonardi; A. Bottini; M. Tucci; M. Milani; A. Angeli; L. Dogliotti
CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS 2004 Daniele Generali; Sara Tedoldi; Alberto Bottini; Alfredo Berruti; Marco Tampellini; Marcello Tucci; Giovanni Allevi; Mirella Torta; Simone Bonardi; Manuela Milani; Sergio Aguggini; Alberto Angeli; Luigi Dogliotti
Circadian rhythm of breakthrough cancer pain. 2011 A. Saini; M. Tucci; K. Bouraouia; P. Ghio; M. Tampellini; P. M. Furlan; L. Ostacoli; L. Dogliotti; A. Berruti
Confronto tra due metodi per la misura della concentrazione della cromogranina A circolante in pazienti con iperplasia prostatica benigna e adenocarcinoma prostatico 2005 Destefanis P.; Berruti A.; Zitella A.; Mongozzi G.; Rosso R.; Casetta G.; Aimo P.; Rolle L.; Greco A.; Dogliotti L.; Fontana D.; Tizzani A.
Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. 2006 Berruti A; Dogliotti L; Tampellini M; Lipton A; Hirsh V; Saad F; Liati P; Shirina N; Cook R; Hei YL
Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. 2006 Bottini A; Generali D; Berruti A; Tampellini M; Torta M; Tedoldi S; Bonardi S; Tucci M; Gorzegno G; Dogliotti L
INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY 2007 Snezana Andrejevic-Blant; Marco Tampellini; Luisella Righi; Irene Alabiso; Veronica Tavaglione; Marco Volante; Luigi Dogliotti; Mauro Papotti; Valerio Marci
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 2011 Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Francesco Leone; Stefania Miraglia; Oscar Alabiso; Massimo Aglietta; Luigi Dogliotti
Low-dose spiral CT for early diagnosis of lung cancer in a light risk population: 2-year results 2004 SCAGLIOTTI GV; BORASIO P; DOGLIOTTI L; FAVA C; CORTESE G; CRIDA B; SELVAGGI G; SAINI; CARDINALE L; PLACIDO R; GRIVETTO S; NOVELLO S.
The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy 2004 M. Tucci; A. Berruti; A. Mosca; G. La Manna; F. Vana; C. Terrone; M. Tampellini; R. Tarabuzzi; G. Gorzegno; L. Dogliotti
THE ONSET OF SKELETAL COMPLICATIONS IN HORMONEREFRACTORY PROSTATE CANCER PATIENTS IS NOT INFLUENCEDBY THE DURATION OF ANDROGEN DEPRIVATION THERAPY 2004 Marcello Tucci; Alfredo Berruti; Alessandra Mosca; Federica Vana; Ginevra La Manna; Carlo Terrone; Marco Tampellini; Roberto Tarabuzzi; Gabriella Gorzegno; Roberto Mario Scarpa; Luigi Dogliotti
The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) 2004 M. Tampellini; A. Saini; I. Alabiso; R. Bitossi; M. P. Brizzi; A. Berruti; G. Gorzegno; S. Miraglia; O. Alabiso; L. Dogliotti
THE ROLE OF HEMOGLOBIN LEVEL IN PREDICTING THE RESPONSE TO FIRST-LINE CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER (ACC) PATIENTS 2004 Marco Tampellini; Andrea Saini; Irene Alabiso; Raffaella Bitossi; Maria Pia Brizzi; Alfredo Berruti; Gabriella Gorzegno; Stefania Miraglia; Oscar Alabiso; Luigi Dogliotti
Survival of lung surgery patients with pulmonary metastases from colonic neoplasms 2008 M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti
TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC) 2006 M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti